Oculis
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 6 months.
- Its last 7 Sell calls were actually followed by a +8% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -54.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 2.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -73.5% | Better than 7% |
| Return on invested capital | -73.2% | Better than 3% |
Momentum F
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -46.0% | Better than 7% |
| 6-month return | -76.1% | Better than 1% |
| 12-month return (ex latest month) | -58.0% | Better than 1% |
| Distance below 52-week high | 79.5% | Better than 2% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.0x | Better than 89% |
| Debt to assets | 1.0% | Better than 93% |
| Interest coverage | -118.0x | Better than 5% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 461.9% | Better than 99% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.44
- Open
- 7.38
- Day range
- 6.98 - 7.43
- Avg price
- 7.14
- Volume
- 235.18K
- Turnover
- 1.68M
- Turnover ratei
- 0.45%
- Volume ratioi
- 1.07
- Amplitudei
- 6.12%
- 52-week rangei
- 6.78 - 34.48
Valuation
- P/Ei
- -3.15
- P/E (TTM)i
- -4.42
- P/Bi
- 1.77
- EPSi
- -2.24
- Book value / shi
- 3.99
- Net profit
- -138.64M
- Net assets
- 247.31M
Share structure
- Market cap
- 437.15M
- Float capi
- 371.21M
- Shares out
- 61.92M
- Float sharesi
- 52.58M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
79.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.77M net over the window
Short interest
- Shares short
- 1.58M
- % of floati
- 2.57%
- Days to coveri
- 5.64
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Oculis (OCS)?
Oculis last traded at 7.06. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Oculis's market cap?
About 437.15M.
What is the P/E ratio of Oculis?
The trailing twelve-month P/E is -4.42. The Valuation tab shows it against the stock's own five-year range.
Does Oculis pay a dividend?
Oculis does not currently pay a regular dividend.
Is Oculis a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 39.67, which implies 461.9% upside from the current price. This is not investment advice.
What is Oculis's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Oculis a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Oculis discussion 0 comments